登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是√否 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二）非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号一一非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 √适用 □不适用 单位：元 币种：人民币 ■ （三）主要会计数据、财务 ...

本公告由創勝集團醫藥有限公司（「本公司」）自願作出，旨在告知本公司股東及潛 在投資者有關最新業務進展。本公告所用但並無另行界定的詞彙應與本公司日期 為2021年9月14日的招股章程中所賦予該等詞彙的涵義相同。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Transcenta Holding Limited 創勝集團醫藥有限公司 （以存續方式於開曼群島註冊的有限公司） （股份代號：6628） 自願公告 有關創勝集團合作夥伴Inhibrx公佈ozekibart治療軟骨肉瘤的 II期臨床試驗積極結果，計劃於2026年遞交BLA的業績進展 創勝集團醫藥有限公司 本公司董事會（「董事會」）欣然公佈，合作夥伴Inhibrx Biosciences, Inc. （「Inhibrx」，納斯達克代碼：INBX）公佈了註冊性臨床研究ChonDRAgon （n=206）的積極主要結果。該研究評估了ozekibart(INBRX-109)單藥相較安慰劑在 晚期或轉移性、 ...

Core Points - The application for the initial public offering (IPO) of Suzhou Fengbei Biotechnology Co., Ltd. has been approved by the Shanghai Stock Exchange and registered by the China Securities Regulatory Commission [1][2] - The IPO price is set at 24.49 yuan per share, with a total issuance of 35.9 million shares, all of which are new shares [2][3] - The strategic placement accounts for 20% of the total issuance, with the final strategic placement amounting to 11.37% after adjustments [3][4] Issuance Details - The issuance combines strategic placement, offline pricing for qualified investors, and online issuance for public investors [2] - The final number of shares for offline issuance is 7,601,703, while online issuance amounts to 24,215,000 shares [4][8] - The overall subscription rate for online issuance reached 8,814.92 times, prompting a mechanism to adjust the allocation between offline and online investors [3][4] Subscription Statistics - Total shares subscribed by online investors: 24,089,076 shares, with a total subscription amount of approximately 589.94 million yuan [8] - Total shares subscribed by offline investors: 7,601,703 shares, with a total subscription amount of approximately 186.17 million yuan [9] - No shares were abandoned by offline investors, while online investors abandoned 125,924 shares [8][9] Lock-up Period and Underwriting - Offline investors are subject to a lock-up period of 6 months for 10% of their allocated shares [10] - The underwriter, Guotai Junan Securities, will underwrite all shares that were abandoned during the subscription process, totaling 125,924 shares [11][12] Issuance Costs - Total issuance costs amount to approximately 84.75 million yuan, including underwriting fees, audit fees, legal fees, and other expenses [13]

发行人：苏州丰倍生物科技股份有限公司 保荐人（主承销商）：国泰海通证券股份有限公司 2025年10月31日 苏州丰倍生物科技股份有限公司（以下简称"丰倍生物""发行人"或"公司"）首次公开发行股票并在主板 上市的申请已经上海证券交易所（以下简称"上交所"）上市审核委员会审议通过，并已经中国证券监督 管理委员会（以下简称"中国证监会"）证监许可〔2025〕1958号文同意注册。《苏州丰倍生物科技股份 有限公司首次公开发行股票并在主板上市招股说明书》及附录在上海证券交易所网站 （www.sse.com.cn）和符合中国证监会规定条件网站（中国证券网，网址www.cnstock.com；中证网， 网址www.cs.com.cn；证券时报网，网址www.stcn.com；证券日报网，网址www.zqrb.cn；经济参考网， 网址www.jjckb.cn；金融时报，网址www.financialnews.com.cn；中国日报，网址 www.chinadaily.com.cn）披露，并置备于发行人、本次发行保荐人（主承销商）国泰海通证券股份有限 公司的住所，供公众查阅。 ■■ ...

两融数据显示，该股最新融资余额为3.16亿元，近5日增加582.89万元，增幅为1.88%。 欧林生物10月30日大宗交易平台共发生9笔成交，合计成交量192.60万股，成交金额3713.32万元。成交价格均为19.28元，相对今日收盘价折价17.99%。从参与大宗交易营业部来看，机构 进一步统计，近3个月内该股累计发生27笔大宗交易，合计成交金额为1.34亿元。 证券时报·数据宝统计显示，欧林生物今日收盘价为23.51元，下跌2.16%，日换手率为1.45%，成交额为1.41亿元，全天主力资金净流入1458.63万元，近5日该股累计上涨3.25%，近5日资 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日，注册资本40593.36万人民币。（数据宝） 10月30日欧林生物大宗交易一览 ...

Group 1 - The company, BioShares, completed a share buyback on October 29, 2023, repurchasing approximately 15.71 million shares, which accounts for 1.4134% of its total share capital [1] - The buyback was executed through centralized bidding, with the highest transaction price at 8.97 CNY per share, the lowest at 6.37 CNY per share, and an average buyback price of 6.9 CNY per share, totaling approximately 108 million CNY in funds used [1] - For the fiscal year 2024, the company's revenue composition is as follows: biopharmaceuticals account for 94.42%, other industries for 3.18%, and other businesses for 2.4% [1]

美佑恒®(注射用维贝柯妥塔单抗)在既往经治过二线及以上系统性化疗及PD-(L)1抑制剂失败后的患者中 显示出临床意义的疗效优势，同时安全性可控。美佑恒®(注射用维贝柯妥塔单抗)用于治疗R/MNPC的 关键注册性临床研究结果于2025年美国临床肿瘤学会年会上以"重磅研究摘要(LBA)"形式公布，并于会 上作口头报告。 此外，美佑恒®(注射用维贝柯妥塔单抗)与普佑恒(普特利单抗注射液)的联合疗法呈现显著且持久的临 床效益，在该联用治疗的II期临床试验中，针对免疫治疗及铂类化疗失败的患者中实现了迄今为止最高 的确认客观缓解率(cORR)(73.3%，95%CI:54.1-87.7)及最长的无进展生存期(mPFS)(10.9m，95%CI:6.6- 15.4)，有望为抗PD-(L)1及铂类化疗失败的R/MNPC患者提供更为有效的治疗选择。上述数据已在2025 年欧洲肿瘤内科学会年会上公布。 格隆汇10月30日丨乐普生物-B(02157.HK)公告，董事会欣然宣布国家药品监督管理局("国家药监局")近 期批准候选药物美佑恒®(注射用维贝柯妥塔单抗)在中国的上市申请，该药物为公司自主研发的一种表 皮生长因子受体("EGF ...

Group 1 - The inclusion of the HPV vaccine in the national immunization program marks a significant breakthrough in public health in China, with over 10 million eligible girls expected to benefit annually from the free vaccination policy starting November 10, 2025 [1][2] - The two-valent HPV vaccine can prevent approximately 70% of cervical cancer cases, which is a major advancement in cervical cancer prevention [1][5] - The market demand for HPV vaccines is projected to reach tens of millions of doses annually, with the market size expected to exceed 10 billion RMB, indicating a substantial growth opportunity for domestic vaccine manufacturers [1][5][6] Group 2 - The government has allocated a budget of approximately 425 million RMB for the centralized procurement of the two-valent HPV vaccine, with an estimated procurement price of 27.5 RMB per dose [5] - The total market size for the national immunization program from 2025 to 2030 is estimated to be around 3.8 billion RMB, which includes both new eligible girls and existing populations needing booster shots [5][6] - The policy is expected to enhance public awareness and willingness to receive HPV vaccinations, potentially increasing demand for self-paid vaccinations among other age groups [5][6] Group 3 - Domestic vaccine companies such as Wantai Biological Pharmacy and Watson Bio are leading the charge in the HPV vaccine market, with significant advancements in technology and production capacity [6][8] - Wantai Biological's two-valent HPV vaccine was the first domestically produced vaccine to break the monopoly of imported vaccines, and the company has also developed the first nine-valent HPV vaccine in China [8][9] - The competition among domestic companies is expected to ensure supply security and drive technological innovation, while also reducing costs and enhancing industry safety and self-sufficiency [9]

Core Insights - NovoCure reported revenue of $167.2 million for the quarter ended September 2025, reflecting a year-over-year increase of 7.8% and a positive surprise of 5.76% over the Zacks Consensus Estimate of $158.1 million [1] - The company's EPS was -$0.33, which is a decline from -$0.28 in the same quarter last year, but it exceeded the consensus estimate of -$0.42 by 21.43% [1] Financial Performance - The revenue growth of 7.8% indicates a solid performance compared to the previous year [1] - The EPS surprise of +21.43% suggests better-than-expected performance in terms of profitability [1] Geographic Revenue Breakdown - Revenue from Greater China was $5.6 million, surpassing the average estimate of $3.65 million [4] - Revenue from Japan reached $9.39 million, slightly above the average estimate of $9.12 million [4] - Revenue from the United States was $96.61 million, exceeding the average estimate of $95.13 million [4] Stock Performance - NovoCure's shares have returned -3.6% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Summary of Changchun High-tech Conference Call Company Overview - **Company**: Changchun High-tech - **Date**: October 30, 2025 Key Points Financial Performance - **Overall Revenue**: Approximately 9.8 billion RMB, with a profit of about 1.165 billion RMB [3] - **Jinsai Pharmaceutical**: Revenue remained stable at 8.213 billion RMB, profit down by approximately 50% [3] - **Baike Pharmaceutical**: Revenue impacted by the return of shingles vaccine, down 53% to about 474 million RMB, resulting in a loss of approximately 158 million RMB [2][3] - **Traditional Chinese Medicine Segment**: Revenue slightly decreased to 542 million RMB, but profit increased by 2% to 36 million RMB [3] - **Real Estate Segment**: Revenue decreased by 8% to 544 million RMB, maintaining a slight profit [3] Product Pipeline and Market Strategy - **Medicare National Negotiation Participation**: Products include long-acting growth hormone Jinsai Zeng, Meishiya, and Children's Golden Granules, with decisions based on pricing [2][5] - **Innovative Drug Pipeline**: Products like NK422 and NK27 have shown preliminary clinical data, with expectations for rapid growth in business development (BD) from 2026 to 2028 [2][6] - **Sales Performance of New Products**: Strong sales momentum for Fuxing Umbilical Monoclonal Antibody, Meishiya, and Children's Golden Granules [2][6] - **Allergy Treatment Collaboration**: Partnership with LK for dust mite desensitization treatment, with plans to establish allergy desensitization centers in major pediatric hospitals [2][7] Clinical Trials and Development - **PD-1 Agonist**: Currently in Phase I clinical trials, with plans for Phase II trials following data disclosure [13] - **Clinical Progress of Meishiya**: Used for cancer anorexia and cachexia treatment, currently enrolling for clinical trials [11] - **Growth Hormone Monthly Formulation**: Adult SAD trials progressing well, transitioning to pediatric CAD trials expected soon [11] Market Challenges and Opportunities - **Non-Entry into Medicare for Jinsai Zeng**: Decision based on anticipated unreasonable pricing from the government; plans to negotiate with commercial insurance [12][14] - **Sales Team Expansion**: Sales team has grown to over 200 members, aiming to cover more than 1,500 hospitals [10][17] - **Focus on Respiratory and Allergy Treatments**: Targeting major diseases like cystic fibrosis and chronic obstructive pulmonary disease (COPD) with innovative products [19] Future Outlook - **Growth Potential**: Despite short-term challenges, long-term growth potential remains strong, especially in innovative drug development and market expansion [21][24] - **Hong Kong Listing Progress**: Normal progress with documents submitted by September 30, aiming for successful issuance next year [22] - **Clinical Pipeline**: 41 clinical pipelines in development, focusing on maximizing potential through continuous R&D [25] Additional Insights - **Market Size for Allergy Treatments**: Approximately 20 million children in China suffer from moderate to severe allergic rhinitis, providing a substantial market opportunity [8] - **Sales Strategy**: Emphasis on professional promotion and market penetration to enhance product visibility and acceptance among healthcare providers [18] This summary encapsulates the key insights from the conference call, highlighting the financial performance, product pipeline, market strategies, and future outlook of Changchun High-tech.